Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients’ quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval and has received orphan drug status in the US. Xspray Pharma’s management team has extensive experience from the pharmaceutical industry. The company is based in Stockholm and shares are traded on Nasdaq Stockholm. www.xspraypharma.com
Looking for a particular XSPRAY PHARMA AB (PUBL) employee's phone or email?
XSPRAY PHARMA AB (PUBL) Questions
The XSPRAY PHARMA AB (PUBL) annual revenue was $7.9 million in 2026.
Linda Glimberg is the COO of XSPRAY PHARMA AB (PUBL).
23 people are employed at XSPRAY PHARMA AB (PUBL).
XSPRAY PHARMA AB (PUBL) is based in Solna, Stockholm.
The NAICS codes for XSPRAY PHARMA AB (PUBL) are [32541, 3254, 325, 32].
The SIC codes for XSPRAY PHARMA AB (PUBL) are [283, 28].
Top XSPRAY PHARMA AB (PUBL) Employees
-
Anna-Karin Ekberg
Vice President, Global Head of Marketing and Sales at XSPRAY PHARMA AB (PUBL)
Uppsala, Uppsala County, SE12 -
Niklas Adenborg
CFO at XSPRAY PHARMA AB (PUBL)
Stockholm, SE -
Jens Landström
Director Project Management and Senior Principal Scientist at XSPRAY PHARMA AB (PUBL)
Stockholm County, Sweden3 -
Jenny Breding
Director Quality Assurance at XSPRAY PHARMA AB (PUBL)
Stockholm County, Sweden3
Related Companies
